title: Strategies for the prevention of cervical cancer by human papillomavirus vaccination.
abstract: As cervical cancer is causally associated with 14 high-risk types of human papillomavirus (HPV), a successful HPV vaccine will have a major impact on this disease. Although some persistent HPV infections progress to cervical cancer, host immunity is generally able to clear most HPV infections. Both cell-mediated and antibody responses have been implicated in influencing the susceptibility, persistence or clearance of genital HPV infection. There have been two clinical trials that show that vaccines based on virus-like particles (VLPs) made from the major capsid protein, L1, are able to type specifically protect against cervical intra-epithelial neoplasia and infection. However, there is no evidence that even a mixed VLP vaccine will protect against types not included in the vaccine, and a major challenge that remains is how to engineer protection across a broader spectrum of viruses. Strategies for production of HPV vaccines using different vaccine vectors and different production systems are also reviewed.
authors.affiliation: Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, and National Health Laboratory Service, Groote Schuur Hospital, Cape Town, South Africa. annalise@curie.uct.ac.za
authors.forename: A-L
authors.initials: AL
authors.lastname: Williamson
authors.forename: J-A
authors.initials: JA
authors.lastname: Passmore
authors.forename: E P
authors.initials: EP
authors.lastname: Rybicki
mesh_terms: D000914:Antibodies, Viral / Q000276:immunology; D001428:Bacterial Vaccines / Q000276:immunology / Q000627:therapeutic use; D016207:Cytokines / Q000276:immunology; D005260:Female; D006679:HIV Seropositivity / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular / Q000276:immunology; D027383:Papillomaviridae / Q000276:immunology*; D030361:Papillomavirus Infections / Q000276:immunology / Q000517:prevention & control*; D008517:Phytotherapy / Q000379:methods; D002583:Uterine Cervical Neoplasms / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D014765:Viral Vaccines / Q000627:therapeutic use*
chemical_list: D000914:Antibodies, Viral; D001428:Bacterial Vaccines; D016207:Cytokines; D014765:Viral Vaccines